We propose a trial of the use of two oral medications metformin and sitagliptin that lower blood sugar without the risk of hypoglycemia. Metformin is first-line therapy for outpatient management of type 2 diabetes. It has long-standing evidence of safety and efficacy. It decreases hepatic glucose production and increases insulin-mediated glucose utilization in the muscle and the liver. A Cochrane Review of 29 trials of metformin as monotherapy compared with other oral agents, insulin, diet, or placebo showed a reduction in cardiovascular events and all-cause mortality with metformin (3).